



OTCQB: DGNOF TSXV : ADK SOURCE : DIAGNOS Inc.

## 2025.02.24

## DIAGNOS to present at Centurion One Capital 8th Annual Toronto Growth Conference

BROSSARD, Quebec, February 24th, 2025 (GLOBE NEWSWIRE) -- Diagnos Inc. ("**DIAGNOS**" or the "**Corporation**") (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (*AI*), is pleased to announce that it will be presenting at the Centurion One Capital 8<sup>th</sup> Annual Conference in Toronto, Canada March 6<sup>th</sup> 2025.

This private event brings together the largest Canadian base of investors looking for the next best investments. DIAGNOS is part of this prestigious event to present its Artificial Intelligence solution for the medical market. DIAGNOS will demonstrate that the market they are going after can be a worldwide success.

"Artificial intelligence will not replace doctors, rather it will empower physicians to practice better medicine with greater accuracy and increase efficiency at unmatched cost. With more data generated than ever, Artificial Intelligence can harness this wealth of information to significantly enhance patient outcomes," said André Larente, CEO of DIAGNOS.

"DIAGNOS is committed to revolutionizing eye health through Artificial Intelligence technologies," added André. "Our expertise in Artificial Intelligence driven diagnostics is helping to improve patient outcomes worldwide. The optometry market comprises over 300,000 sites globally. Our recent partnership with the largest player in the industry has not only validated our technology, but will significantly boost our visibility. Additionally, our government-related business initiatives are resuming, marking an exciting phase of growth for DIAGNOS."

## About DIAGNOS

DIAGNOS is a publicly traded Canadian corporation dedicated to early detection of critical health problems based on its FLAIRE Artificial Intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications such as CARA (Computer Assisted Retina Analysis). CARA's image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients.

Additional information is available at <u>www.diagnos.ca</u> and <u>www.sedarplus.com</u>.

For further information, please contact:

Mr. André Larente, President DIAGNOS Inc.

Tel: 450-678-8882 ext. 224 alarente@diagnos.ca

This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

– 30 –